This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (93)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Genetic Disorders  • Venous Thromboembolism  • Alert me on articles by topic

Jeanet W. Blom, MD; Carine J. M. Doggen, PhD; Susanne Osanto, MD, PhD; Frits R. Rosendaal, MD, PhD

JAMA. 2005;293:715-722.

Context  Venous thrombosis is a common complication in patients with cancer, leading to additional morbidity and compromising quality of life.

Objective  To identify individuals with cancer with an increased thrombotic risk, evaluating different tumor sites, the presence of distant metastases, and carrier status of prothrombotic mutations.

Design, Setting, and Patients  A large population-based, case-control (Multiple Environmental and Genetic Assessment [MEGA] of risk factors for venous thrombosis) study of 3220 consecutive patients aged 18 to 70 years, with a first deep venous thrombosis of the leg or pulmonary embolism, between March 1, 1999, and May 31, 2002, at 6 anticoagulation clinics in the Netherlands, and separate 2131 control participants (partners of the patients) reported via a questionnaire on acquired risk factors for venous thrombosis. Three months after discontinuation of the anticoagulant therapy, all patients and controls were interviewed, a blood sample was taken, and DNA was isolated to ascertain the factor V Leiden and prothrombin 20210A mutations.

Main Outcome Measure  Risk of venous thrombosis.

Results  The overall risk of venous thrombosis was increased 7-fold in patients with a malignancy (odds ratio [OR], 6.7; 95% confidence interval [CI], 5.2-8.6) vs persons without malignancy. Patients with hematological malignancies had the highest risk of venous thrombosis, adjusted for age and sex (adjusted OR, 28.0; 95% CI, 4.0-199.7), followed by lung cancer and gastrointestinal cancer. The risk of venous thrombosis was highest in the first few months after the diagnosis of malignancy (adjusted OR, 53.5; 95% CI, 8.6-334.3). Patients with cancer with distant metastases had a higher risk vs patients without distant metastases (adjusted OR, 19.8; 95% CI, 2.6-149.1). Carriers of the factor V Leiden mutation who also had cancer had a 12-fold increased risk vs individuals without cancer and factor V Leiden (adjusted OR, 12.1; 95% CI, 1.6-88.1). Similar results were indirectly calculated for the prothrombin 20210A mutation in patients with cancer.

Conclusions  Patients with cancer have a highly increased risk of venous thrombosis especially in the first few months after diagnosis and in the presence of distant metastases. Carriers of the factor V Leiden and prothrombin 20210A mutations appear to have an even higher risk.

Author Affiliations: Departments of Clinical Epidemiology (Drs Blom, Doggen, and Rosendaal) and Oncology (Dr Osanto), and Hemostasis and Thrombosis Research Center (Dr Rosendaal), Leiden University Medical Center, Leiden, the Netherlands.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Development and validation of a predictive model for chemotherapy-associated thrombosis
Khorana et al.
Blood 2008;111:4902-4907.
ABSTRACT | FULL TEXT  

Use of Thromboprophylaxis in Palliative Care Patients: A Survey Among Experts in Palliative Care, Oncology, Intensive Care, and Anticoagulation
Kierner et al.
AM J HOSP PALLIAT CARE 2008;25:127-131.
ABSTRACT  

Gene Variants Associated With Deep Vein Thrombosis
Bezemer et al.
JAMA 2008;299:1306-1314.
ABSTRACT | FULL TEXT  

Gene Discovery in Venous Thrombosis: Progress and Promise
Bovill
JAMA 2008;299:1362-1363.
FULL TEXT  

American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
Lyman et al.
JCO 2007;25:5490-5505.
ABSTRACT | FULL TEXT  

The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: Strategies for Improving VTE Prophylaxis in Hospitalized Cancer Patients
Khorana
The Oncologist 2007;12:1361-1370.
ABSTRACT | FULL TEXT  

Trousseau's syndrome: multiple definitions and multiple mechanisms
Varki
Blood 2007;110:1723-1729.
ABSTRACT | FULL TEXT  

Nonbacterial Thrombotic Endocarditis in Cancer Patients: Pathogenesis, Diagnosis, and Treatment
el-Shami et al.
The Oncologist 2007;12:518-523.
ABSTRACT | FULL TEXT  

Thromboembolic Events in Children and Young Adults With Pediatric Sarcoma
Paz-Priel et al.
JCO 2007;25:1519-1524.
ABSTRACT | FULL TEXT  

No Association Between the Common MTHFR 677C->T Polymorphism and Venous Thrombosis: Results From the MEGA Study
Bezemer et al.
Arch Intern Med 2007;167:497-501.
ABSTRACT | FULL TEXT  

Incidence of Venous Thromboembolism and the Impact on Survival in Breast Cancer Patients
Chew et al.
JCO 2007;25:70-76.
ABSTRACT | FULL TEXT  

Thrombophilia: Common Questions on Laboratory Assessment and Management
Heit
ASH Education Book 2007;2007:127-135.
ABSTRACT | FULL TEXT  

Management of Thrombohemorrhagic Syndromes (THS) in Hematologic Malignancies
Falanga and Rickles
ASH Education Book 2007;2007:165-171.
ABSTRACT | FULL TEXT  

Decreased Risk of Stroke Among 10-Year Survivors of Breast Cancer
Hooning et al.
JCO 2006;24:5388-5394.
ABSTRACT | FULL TEXT  

Venous thromboembolic disease and cancer.
Fennerty
Postgrad. Med. J. 2006;82:642-648.
ABSTRACT | FULL TEXT  

Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients
Caruso et al.
Blood 2006;108:2216-2222.
ABSTRACT | FULL TEXT  

Thromboembolism in cancer patients: pathogenesis and treatment.
Adess et al.
CLIN APPL THROMB HEMOST 2006;12:254-266.
ABSTRACT  

Management of Venous Thromboembolism in Patients With Primary and Metastatic Brain Tumors
Gerber et al.
JCO 2006;24:1310-1318.
ABSTRACT | FULL TEXT  

Targeting angiogenesis with integrative cancer therapies.
Yance and Sagar
Integr Cancer Ther 2006;5:9-29.
ABSTRACT  

Venous Thromboembolism in Patients With Colorectal Cancer: Incidence and Effect on Survival
Alcalay et al.
JCO 2006;24:1112-1118.
ABSTRACT | FULL TEXT  

Catheter-associated thrombosis: thromboprophylaxis for cancer patients who carry factor V Leiden?
Ferretti et al.
Ann Oncol 2006;17:528-529.
FULL TEXT  

Protease-Activated Receptor-2 Is Essential for Factor VIIa and Xa-Induced Signaling, Migration, and Invasion of Breast Cancer Cells
Morris et al.
Cancer Res. 2006;66:307-314.
ABSTRACT | FULL TEXT  

Thrombosis and Cancer: The Role of Screening for Occult Cancer and Recognizing the Underlying Biological Mechanisms
Lee
ASH Education Book 2006;2006:438-443.
ABSTRACT | FULL TEXT  

How I treat venous thromboembolism in patients with cancer
Prandoni
Blood 2005;106:4027-4033.
ABSTRACT | FULL TEXT  

Venous Thromboembolism (VTE) in Hematologic Malignancies(HM).
Korin et al.
ASH ANNUAL MEETING ABSTRACTS 2005;106:4108-4108.
ABSTRACT  

Patients with cancer are at high risk of venous thrombosis
Mayor
BMJ 2005;330:326.
FULL TEXT  

Venous Thrombosis: The Role of Genes, Environment, and Behavior
Rosendaal
ASH Education Book 2005;2005:1-12.
ABSTRACT | FULL TEXT  

Acquired Risk Factors for Venous Thromboembolism in Medical Patients
Prandoni
ASH Education Book 2005;2005:458-461.
ABSTRACT | FULL TEXT